The Reduced Expression Level of MST1 gene in Patients with Prostate Cancer

  • Fariba Karimian Department of Medical Biotechnology, Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
  • Mehdi Sahmani Department of Medical Biotechnology, Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
  • Amirhosein Maali Department of Medical Biotechnology, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran
  • Taghi Naserpour Farivar Department of Medical Biotechnology, Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
  • Ali Akbar Karimi Urology Research Center, Sina Hospital, Medical Sciences/University of Tehran, Tehran, Iran
  • Mehdi Azad Department of Medical laboratory sciences, Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
Keywords: Prostate cancer, MST1, STK4, Hippo signaling, Transcriptomics, Biomarker

Abstract

  Background: Prostate cancer (PC) is the second most common malignancy in men, accounting for 12.5% of total number of cancers. The development of molecular studies (such as transcriptomics analysis) helps to characterization of Cancer, development of new targets for therapy, and introduction of the novel prognostic and diagnostic biomarkers. Recent studies have confirmed Mammalian Sterile 20-Like kinase (MST1) as a tumor suppressor gene. In this study we focus on MST1 expression level in WBC of PC patients, due to inheritance pattern of PC.  Material and Methods: This case-control study was conducted in two groups (20 patients with PC and 20 healthy individuals). After RNA extraction and cDNA synthesis, quantitative Real-Time PCR was done in order to determine the MST1 expression level. GAPDH was considered as internal control gene. Statistical analysis was performed by “Rotor-Gene Q series software 2.3.1” and “Rest 2.0.13 software”. Results: the study on 20 PC patients aged 50 to 70 years old and 20 healthy individuals shown that MST1 expression level in the WBC samples of PC patients have been reduced ≈62% compared to normal individuals. Conclusion: Introducing of reduced expression level of MST1 as a prostate cancer biomarker needs to more complementary studies. But in this study, biomarker validation potential of MST1 has been approved.

Author Biography

Mehdi Azad, Department of Medical laboratory sciences, Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
corresponding author

References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. 2015;136(5):E359-E86.
2. Schulz W, Burchardt M, Cronauer M. Molecular biology of prostate cancer. Molecular human reproduction. 2003;9(8):437-48.
3. Brunet Vega A, Pericay C, Moya I, Ferrer A, Dotor E, Pisa A, et al. microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. Oncology reports. 2013;30(1):320-6.
4. Seidel C, Schagdarsurengin U, Blümke K, Würl P, Pfeifer GP, Hauptmann S, et al. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Molecular carcinogenesis. 2007;46(10):865-71.
5. Zhou D, Conrad C, Xia F, Park J-S, Payer B, Yin Y, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer cell. 2009;16(5):425-38.
6. Rawat SJ, Chernoff J. Regulation of mammalian Ste20 (Mst) kinases. Trends in biochemical sciences. 2015;40(3):149-56.
7. Gumbiner BM, Kim N-G. The Hippo-YAP signaling pathway and contact inhibition of growth. J Cell Sci. 2014;127(4):709-17.
8. O'Neill EE, Matallanas D, Kolch W. Mammalian sterile 20–like kinases in tumor suppression: An emerging pathway. Cancer research. 2005;65(13):5485-7.
9. Thompson BJ, Sahai E. MST kinases in development and disease. J Cell Biol. 2015;210(6):871-82.
10. Babel I, Barderas R, Díaz-Uriarte R, Martínez-Torrecuadrada JL, Sánchez-Carbayo M, Casal JI. Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays. Molecular & cellular proteomics. 2009;8(10):2382-95.
11. Pan D. The hippo signaling pathway in development and cancer. Developmental cell. 2010;19(4):491-505.
12. Wong RS. Apoptosis in cancer: from pathogenesis to treatment. Journal of Experimental & Clinical Cancer Research. 2011;30(1):87.
13. Kiraz Y, Adan A, Yandim MK, Baran Y. Major apoptotic mechanisms and genes involved in apoptosis. Tumor Biology. 2016;37(7):8471-86.
14. Lee Y-C, Yang C-N, Hsu T-I, Lu P-J. STK4 downregulation promotes tumor invasion/migration and is associated with poor prognosis in human colon cancer. AACR; 2013.
15. Minoo P, Zlobec I, Baker K, Tornillo L, Terracciano L, Jass JR, et al. Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer. Modern pathology. 2007;20(3):331.
16. Frau M, Biasi F, Feo F, Pascale RM. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma. Molecular aspects of medicine. 2010;31(2):179-93.
17. Li W, Xiao J, Zhou X, Xu M, Hu C, Xu X, et al. STK4 regulates TLR pathways and protects against chronic inflammation–related hepatocellular carcinoma. The Journal of clinical investigation. 2015;125(11):4239-54.
18. Zhai X-H, Yu J-K, Yang F-Q, Zheng S. Identification of a new protein biomarker for colorectal cancer diagnosis. Molecular medicine reports. 2012;6(2):444-8.
19. Mazaris E, Tsiotras A. Molecular pathways in prostate cancer. Nephro-urology monthly. 2013;5(3):792.
20. Tang F, Zhang L, Xue G, Hynx D, Wang Y, Cron PD, et al. hMOB3 modulates MST1 apoptotic signaling and supports tumor growth in glioblastoma multiforme. Cancer research. 2014.
21. Kim T-S, Lee D-H, Kim SK, Shin SY, Seo E-J, Lim D-S. Mammalian sterile 20-like kinase 1 (Mst1) suppresses lymphoma development by promoting faithful chromosome segregation. Cancer research. 2012:canres. 3956.2011.
Published
2019-01-06
How to Cite
1.
Karimian F, Sahmani M, Maali A, Naserpour Farivar T, Karimi AA, Azad M. The Reduced Expression Level of MST1 gene in Patients with Prostate Cancer. BCCR. 11(1).
Section
Original Articles